Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

L.A. McKeown

July 24, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Features

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

L.A. McKeown

December 02, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Daily News

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

L.A. McKeown

April 09, 2021

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Top Endovascular News of 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

FDA Approves Bioresorbable Scaffold for BTK Lesions

Top Endovascular News of 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

Top Endovascular News of 2022

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content